Patterns of use and dosing of tocilizumab in the treatment of patients with rheumatoid arthritis in routine clinical practice: the ACT-LIFE study

Rheumatology International
Alejandro BalsaVicente Vila

Abstract

The aim of the study was to identify and describe the patterns of use of tocilizumab in clinical practice to ensure safety and optimal management of rheumatoid arthritis (RA). This is a 12-month prospective observational study in patients with moderate or severe RA of ≥6 months' duration who have started tocilizumab after failure of at least one previous disease-modifying antirheumatic drug (DMARD) including TNF inhibitors. For some analyses, patients were categorized by the use of tocilizumab as monotherapy or in combination, and by previous use of biological therapy. Overall, 379 were evaluable (84.4 % received tocilizumab after prior biologics and 78.4 % in combination with classic DMARDs). Tocilizumab was discontinued in 68/379 (17.9 %) patients after a median of 6.7 (3.7-10.4) months, mainly due to a lack of efficacy (24/379, 6.3 %) and adverse events (23/379, 6.1 %). Of 131 temporary interruptions of tocilizumab required in 101/379 (26.6 %) patients, 81/131 (61.8 %) were related to adverse events, and in 120/131 (91.6 %) cases, tocilizumab was reintroduced at 8 mg/kg. Thirty-six tocilizumab dose reductions occurred in 34/379 (9 %) patients due to abnormal laboratory values in 20/34 (55.6 %) cases. DAS28-ESR scores decreas...Continue Reading

References

Mar 6, 2004·Lancet·Lars KlareskogUNKNOWN TEMPO (Trial of Etanercept and Methotrexate with Radiographic Patient Outcomes) study investigators
Jul 26, 2005·Joint, Bone, Spine : Revue Du Rhumatisme·Daniel WendlingMarie-Christine Woronoff-Lemsi
Oct 29, 2005·Arthritis and Rheumatism·Joachim ListingAngela Zink
May 17, 2007·Rheumatology·S BombardieriUNKNOWN Research in Active Rheumatoid Arthritis (ReAct) Study Group
Jun 16, 2007·Lancet·Josef S SmolenPaul Emery
Oct 16, 2008·Annals of the Rheumatic Diseases·Josef S Smolen, Michael E Weinblatt
May 1, 2009·Arthritis and Rheumatism·Sophie Martin Du PanUNKNOWN Swiss Clinical Quality Management Physicians
Sep 18, 2009·Annals of the New York Academy of Sciences·Antonio MarchesoniEnnio Giulio Favalli
Feb 18, 2011·The Cochrane Database of Systematic Reviews·Jasvinder A SinghRachelle Buchbinder
Feb 19, 2011·Annals of the Rheumatic Diseases·Moetaza M SolimanUNKNOWN British Society for Rheumatology Biologics Register
May 10, 2011·Annals of the Rheumatic Diseases·Henrik Christian LeffersUNKNOWN all departments of rheumatology in Denmark
Jan 24, 2013·Therapeutic Advances in Chronic Disease·Atsushi Kaneko
Mar 9, 2013·Scandinavian Journal of Rheumatology·Y HishitaniA Kumanogoh

❮ Previous
Next ❯

Citations

May 14, 2016·Reumatología clinica·Irene Notario FerreiraRafael Cáliz Cáliz
Mar 3, 2018·Immunotherapy·Raimon SanmartíDolor Soy

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.